This study provides evidence that targeting LAIR-1+ leukemic cells with a LAIR-1 agonist mAb is an effective approach for inhibiting and killing AML blasts and LSCs while sparing normal HSCs. This evidence concerns the gene LAIR1 and acute myeloid leukemia.